Reply to: Therapeutic Strategy Concerns for BRAF V600E–Mutated Differentiated Thyroid Cancer
Journal of Clinical Oncology · 20.11.2026 · 44 (33) · 3285-3286
DOI: 10.1200/jco-26-01611 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.11.2026. Verfasst von Nabil F Saba und 3 weiteren Autor:innen. Beteiligte Einrichtung: Nabil F. Saba, MD, Emory University, Atlanta, GA, Nofisat Ismaila, MD, American Society of Clinical Oncology (ASCO), Alexandria, VA, Francis Worden, …. Die Arbeit nennt 6 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Nabil F. Saba, MD, Emory University, Atlanta, GA, Nofisat Ismaila, MD, American Society of Clinical Oncology (ASCO), Alexandria, VA, Francis Worden, MD, University of Michigan Rogel Cancer Center, Ann Arbor, MI, Beth M.…
ORCID-Profile: Nabil F Saba, Nofisat Ismaila, Beth M Beadle
Zitieren
APA
Saba, N. F., Ismaila, N., Worden, F., & Beadle, B. M. (2026). Reply to: Therapeutic Strategy Concerns for BRAF V600E–Mutated Differentiated Thyroid Cancer. Journal of Clinical Oncology, 44(33), 3285-3286. https://doi.org/10.1200/jco-26-01611
Vancouver
Saba NF, Ismaila N, Worden F, Beadle BM. Reply to: Therapeutic Strategy Concerns for BRAF V600E–Mutated Differentiated Thyroid Cancer. Journal of Clinical Oncology. 2026;44(33):3285-3286. doi:10.1200/jco-26-01611
BibTeX
@article{Saba2026,
author = {Saba, Nabil F and Ismaila, Nofisat and Worden, Francis and Beadle, Beth M},
title = {Reply to: Therapeutic Strategy Concerns for BRAF V600E–Mutated Differentiated Thyroid Cancer},
journal = {Journal of Clinical Oncology},
year = {2026},
volume = {44},
number = {33},
pages = {3285--3286},
doi = {10.1200/jco-26-01611}
}
EUVIMED